NCT07089719Not yet recruitingPhase 2
Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
Source: ClinicalTrials.gov · Last updated 28 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection. The study seeks to determine whether Bevacizumab can improve breathing capacity by acting on vascular mechanisms that may be responsible for these issues. A total of 21 patients with these persistent symptoms will be included in the study, with close medical monitoring to assess both the effectiveness of the treatment and its safety. This research aims to assess the effectiveness and safety of Bevacizumab, a medication known for its anti-angiogenic properties (which prevent the formation of new blood vessels), in patients experiencing persistent respiratory problems after COVID-19 infection. In other words, this research is based on the idea that inhibiting blood vessel formation with Bevacizumab may improve clinical outcomes in patients with severe forms of COVID-19 by reducing vascular complications associated with the infection. To answer this research question, 21 individuals with persistent respiratory symptoms (significant dyspnea) and reduced lung diffusing capacity (DLCO less than 75% of the predicted value) at least three months after their initial COVID-19 infection will be included. The study is being conducted at Hôpital Européen Georges Pompidou, in Paris. The total expected duration of the research is 31 months, and each patient's participation will last 7 months, which includes 2 months of treatment (five Bevacizumab injections) followed by five additional months of medical follow-up. In this research project, we will be evaluating Bevacizumab, an experimental drug in the context of Long COVID. Bevacizumab is a monoclonal antibody used to inhibit angiogenesis (the abnormal formation of new blood vessels). While commonly used in oncology, in this study, its use aims to improve lung function in patients suffering from persistent respiratory complications after COVID-19 infection. Bevacizumab will be administered as an intravenous infusion. The infusion lasts between 30 and 90 minutes. The dosage is 10 mg/kg every two weeks, for a total of five infusions over a two-month period. Additional follow-up visits will be conducted one month and five months after the end of treatment. Monitoring will include clinical examinations, laboratory tests, and lung function assessments.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 21 Jul 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07089719
- EU CT number
- 2024-520308-24-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 21
- From 1 Oct 2025 to the primary completion date, 1 Jan 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction or stroke less than 3 months before screening
- Previous osteonecrosis
- Surgery in 28 days before inclusion
- Participation in another interventional study or being in the exclusion period at the end of a previous study
Other illness
- Acute COVID-19 infection
- Uncontrolled hypertension (\> 140/90 at inclusion in the study)
- History of malignant hypertension
- History of Aneurysm and artery dissections
- Active cancer
- Known hypersensitivity to bevacizumab or any ingredient in its formulation, including non-medicinal ingredients, or a component of the container
- Hypersensitivity to Chinese Hamster Ovary (CHO) cell product or other recombinant human or humanized antibodies
- History of radiotherapy
- History of bisphosphonates treatment
Age
- Lung scintigraphy and thoracic CT angiography evaluation to rule out pulmonary embolism less than 3 months old on the day of screening or to be obtained before Day 1 if older than 3 months to exclude Sequelae of pulmonary embolism or lung emphysema in the setting of COPD
Other
- Women of childbearing potential
- Proteinuria/creatinuria ratio \> 1 g/mmol at baseline DFG \< 30 ml/min
- Patient unable or unwilling to comply with the follow up schedule (at the investigator's discretion)
- Pregnant or breastfeeding women
- Vulnerable populations (patient under gardianship, curatorship, deprived of liberty)
- Patient on AME (State medical aid)
Who the study is looking for
- Patients over 18 years, under 90 years
- Social security affiliation
- Good understanding of the French language
- Written informed consent
- DOcumented COVID-19 infection (PCR or CT-scan) more than 3 months before inclusion
- Long COVID suspicion with dyspnea (mMRC \> 2 at inclusion)
- DLCO \< 75% of predicted value less than 3 months old on the day of screening or to be obtained before Day 1 older than 3 months
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HEGP, department of Physiology Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| HEGP, clinical investigation center Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.